Coverart for item
The Resource Neuroprotective therapy for stroke and ischemic disease, Paul A. Lapchak, John H. Zhang, editors

Neuroprotective therapy for stroke and ischemic disease, Paul A. Lapchak, John H. Zhang, editors

Label
Neuroprotective therapy for stroke and ischemic disease
Title
Neuroprotective therapy for stroke and ischemic disease
Statement of responsibility
Paul A. Lapchak, John H. Zhang, editors
Contributor
Editor
Subject
Language
eng
Summary
This book is a critical and comprehensive look at current state-of-the-art scientific and translational research being conducted internationally, in both academia and industry; it serves to address new ways to provide effective treatment to victims of ischemic and hemorrhagic stroke and other ischemic diseases. Currently, stroke can be successfully treated through the administration of a thrombolytic, but the therapeutic window is short and many patients are not able to receive treatment. Only about 30% of patients are "cured" by available treatments. Divided into five sections, the proposed volume explores historical and novel neuroprotection mechanisms and targets, new and combination therapies, as well as clinical trial design for some of the most recent bench-side research
Member of
Cataloging source
N$T
Dewey number
  • 616.8/1
  • 610
Index
index present
LC call number
RC388.5
Literary form
non fiction
Nature of contents
dictionaries
http://library.link/vocab/relatedWorkOrContributorName
  • Lapchak, Paul A.
  • Zhang, J. H.
Series statement
Springer series in translational stroke research,
http://library.link/vocab/subjectName
  • Cerebrovascular disease
  • Ischemia
  • Neuroprotective agents
  • Brain Ischemia
  • Biomedicine
  • Neurosciences
  • Cardiology
Label
Neuroprotective therapy for stroke and ischemic disease, Paul A. Lapchak, John H. Zhang, editors
Instantiates
Publication
Note
Includes index
Antecedent source
unknown
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Preface; Contents; Contributors; Part I: Stroke Neuroprotection: The History and Learning Experience; Chapter 1: Reflections on Neuroprotection Research and the Path Toward Clinical Success; 1 Introduction: A Brief Chronological History of Stroke; 1.1 Of Neurons and Time; 1.1.1 Extrapolated Stroke and Cerebrovascular Disease Incidence; 1.1.2 Time-brain matters!; 2 Limited Benefit Treatment Options for Acute Ischemic Stroke Victims: Successes!; 2.1 Thrombolysis: Thrombolytic Therapy; 2.2 Endovascular Procedures and Thrombolysis; 2.2.1 ESCAPE [32]: Table 1.3; 2.2.2 EXTEND-IA [33]: Table 1.4
  • 2.2.3 MR CLEAN [31]: Table 1.52.2.4 REVASCAT [34]: Table 1.6; 2.2.5 SWIFT-PRIME [35]: Table 1.7; 2.2.6 Endovascular Procedure Benefit; 2.3 Embolectomy Concerns; 2.3.1 Patient Population Selection for Embolectomy and Thrombolysis; 2.3.2 Limitations of the Trials; Patient Selection Bias; Saving Penumbra; Time to Treatment; Coadministration of Thrombolytics; 2.3.3 Future of Embolectomy; Endovascular Procedure Summary; 3 Neuroprotection; 3.1 Evolving Opportunities; 3.2 The RIGORs of Drug Development: Guideline Adherence; 3.3 Meta-analysis of Translational Studies; 4 Comorbidities and Models
  • 4.1 Hypertension Models4.2 Diabetic Models; 4.2.1 Coadministration of Drugs in Stroke Models; 5 Drug Development Considerations; 6 Conclusion; References; Chapter 2: Systematic Review and Meta-analysis: Important Tools in Understanding Drug Development for Stroke; 1 Introduction; 2 Evidence-Based Approaches to Understanding Translational Stroke Research; 2.1 Assessing the Quality and Range of Available Evidence; 2.1.1 Quality of Evidence; 2.1.2 Range of Evidence; 2.2 Assessing for Publication Bias; 2.3 Impacts of Systematic Reviews
  • 2.4 Providing Potential Explanations for Discrepancies Between Preclinical and Clinical Trial Results2.5 Informing Clinical Trial Design; 3 Limitations of Systematic Review and Meta-analysis; 4 Future of Preclinical Systematic Review and Meta-analysis; 5 Conclusions; 6 Resources; References; Chapter 3: Neuroprotection Is Technology, Not Science; 1 Introduction; 2 Part 1: Physics and Biology; 2.1 A Tale of Two Cultures; 2.2 What Is Measured?; 2.3 The Mathematizing of Biology; 3 Part 2: A Theory of Acute Cell Injury; 3.1 Introduction to the Theory; 3.2 Qualitative Description of the Theory
  • 3.3 The Autonomous Theory3.4 Solutions of the Autonomous Theory; 3.5 Monostable Outcome; 3.6 Bistable Outcome; 3.7 Pre-treatment Therapies; 3.8 Closed Trajectories and the Autonomous Theory; 4 Technological Applications; 4.1 Approaches to Therapy; 4.2 Ascertaining Injury Intensity; 4.3 Protective Therapeutics; 4.4 The Non-autonomous Dynamical Theory of Acute Cell Injury; 4.5 Sequential Injuries; 4.6 Solutions of the Multiple Injury Model; 4.6.1 Preconditioning; 4.6.2 Post-injury Drug Treatment; 4.7 Spatial Applications; 4.8 A Possible Neuroprotective Technology
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9783319453453
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-3-319-45345-3
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
ocn968705998
Label
Neuroprotective therapy for stroke and ischemic disease, Paul A. Lapchak, John H. Zhang, editors
Publication
Note
Includes index
Antecedent source
unknown
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Preface; Contents; Contributors; Part I: Stroke Neuroprotection: The History and Learning Experience; Chapter 1: Reflections on Neuroprotection Research and the Path Toward Clinical Success; 1 Introduction: A Brief Chronological History of Stroke; 1.1 Of Neurons and Time; 1.1.1 Extrapolated Stroke and Cerebrovascular Disease Incidence; 1.1.2 Time-brain matters!; 2 Limited Benefit Treatment Options for Acute Ischemic Stroke Victims: Successes!; 2.1 Thrombolysis: Thrombolytic Therapy; 2.2 Endovascular Procedures and Thrombolysis; 2.2.1 ESCAPE [32]: Table 1.3; 2.2.2 EXTEND-IA [33]: Table 1.4
  • 2.2.3 MR CLEAN [31]: Table 1.52.2.4 REVASCAT [34]: Table 1.6; 2.2.5 SWIFT-PRIME [35]: Table 1.7; 2.2.6 Endovascular Procedure Benefit; 2.3 Embolectomy Concerns; 2.3.1 Patient Population Selection for Embolectomy and Thrombolysis; 2.3.2 Limitations of the Trials; Patient Selection Bias; Saving Penumbra; Time to Treatment; Coadministration of Thrombolytics; 2.3.3 Future of Embolectomy; Endovascular Procedure Summary; 3 Neuroprotection; 3.1 Evolving Opportunities; 3.2 The RIGORs of Drug Development: Guideline Adherence; 3.3 Meta-analysis of Translational Studies; 4 Comorbidities and Models
  • 4.1 Hypertension Models4.2 Diabetic Models; 4.2.1 Coadministration of Drugs in Stroke Models; 5 Drug Development Considerations; 6 Conclusion; References; Chapter 2: Systematic Review and Meta-analysis: Important Tools in Understanding Drug Development for Stroke; 1 Introduction; 2 Evidence-Based Approaches to Understanding Translational Stroke Research; 2.1 Assessing the Quality and Range of Available Evidence; 2.1.1 Quality of Evidence; 2.1.2 Range of Evidence; 2.2 Assessing for Publication Bias; 2.3 Impacts of Systematic Reviews
  • 2.4 Providing Potential Explanations for Discrepancies Between Preclinical and Clinical Trial Results2.5 Informing Clinical Trial Design; 3 Limitations of Systematic Review and Meta-analysis; 4 Future of Preclinical Systematic Review and Meta-analysis; 5 Conclusions; 6 Resources; References; Chapter 3: Neuroprotection Is Technology, Not Science; 1 Introduction; 2 Part 1: Physics and Biology; 2.1 A Tale of Two Cultures; 2.2 What Is Measured?; 2.3 The Mathematizing of Biology; 3 Part 2: A Theory of Acute Cell Injury; 3.1 Introduction to the Theory; 3.2 Qualitative Description of the Theory
  • 3.3 The Autonomous Theory3.4 Solutions of the Autonomous Theory; 3.5 Monostable Outcome; 3.6 Bistable Outcome; 3.7 Pre-treatment Therapies; 3.8 Closed Trajectories and the Autonomous Theory; 4 Technological Applications; 4.1 Approaches to Therapy; 4.2 Ascertaining Injury Intensity; 4.3 Protective Therapeutics; 4.4 The Non-autonomous Dynamical Theory of Acute Cell Injury; 4.5 Sequential Injuries; 4.6 Solutions of the Multiple Injury Model; 4.6.1 Preconditioning; 4.6.2 Post-injury Drug Treatment; 4.7 Spatial Applications; 4.8 A Possible Neuroprotective Technology
Dimensions
unknown
Extent
1 online resource.
File format
unknown
Form of item
online
Isbn
9783319453453
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Other control number
10.1007/978-3-319-45345-3
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
ocn968705998

Library Locations

Processing Feedback ...